Subcutaneous rituximab injectables are formulated with recombinant human hyaluronidase as an adjunct to facilitate the absorption of the large volume of rituximab. We review the clinical considerations regarding the potential for systemic hyaluronidase toxicity and increased systemic absorption of subcutaneous or topical drugs administered subsequent to rituximab.
Genentech. Rituximab SC presentation to the Oncology Drug Advisory Committee. Bethesda, MD; 29 March 2017.
2.
Halozyme Therapeutics, Inc. Hylenex product monograph. San Diego, CA; February 2016.
3.
FrostGI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv2007; 4: 427–440.
4.
LiptrottSCambonNBerthillonNet al.Minimization of administration route errors with subcutaneous rituximab. J Oncol Pharm Pract2016; 22: 186–187.
AssoulineSBuccheriVDelmerAet al.Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol2015; 80: 1001–1009.
7.
Aspen Pharmacare Canada Inc. EMLA product monograph. Toronto, Ontario; 8 August 2016.
8.
Aspen Pharmacare Canada Inc. EMLA cream product monograph. Dublin, Ireland; 27 May 2017.
